Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Dara-VRd for newly diagnosed myeloma: efficacy and safety data

Peter Voorhees • 4 Dec 2018
ASH 2018
Multiple Myeloma Bortezomib Daratumumab Dexamethasone Lenalidomide
GRIFFIN

Peter Voorhees, MD, of Levine Cancer Institute, Charlotte, NC, discusses the safety and efficacy results for daratumumab, bortezomib, lenalidomide and dexamethasone (dara‐VRd) in ASCT-eligible newly diagnosed multiple myeloma patients from the Phase II GRIFFIN study (NCT02874742). Dr Voorhees reveals the encouraging tolerability, safety and response data from this trial.

More from Peter Voorhees

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting 11:32
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting
Holly Lee et al. • 24 Oct 2025
Promising cellular therapies emerging in multiple myeloma 2:42
Promising cellular therapies emerging in multiple myeloma
Peter Voorhees • 30 Sep 2022
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab 4:15
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Peter Voorhees • 30 Sep 2022

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals